Pacira BioSciences, Inc. PCRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.92M-39.4% | $1.64M— | $5.43M+104% | -$4.85M-126% | $4.81M-46.4% | ||
| $21.33M+0.8% | $21.34M+0.5% | $21.19M+4.6% | $27.32M+44.8% | $21.17M+14.9% | ||
| $13.54M-7.0% | $13.5M+10.1% | $13.98M+5.7% | $15.47M+23.5% | $14.55M+10.7% | ||
| $1.73M+23.8% | —— | $8.07M+624% | $752K-94.0% | $1.4M-59.7% | ||
| $577K-33.4% | $677K-27.8% | $626K-25.5% | $849K+11.3% | $867K+27.3% | ||
| $1.57M+118% | $8.8M-30.4% | $897K+122% | $9.61M+206% | -$8.56M-119% | ||
| -$2.49M-129% | —— | $9.51M+12.9% | $14.4M+116% | $8.47M+212% | ||
| -$936K-138% | -$2.93M— | -$12.01M-1,986% | $6.88M-29.4% | $2.46M+135% | ||
| -$10.31M-319% | $14M— | $7.53M-32.7% | -$19.38M— | $4.7M+35.5% | ||
| $4.54M-12.8% | —— | —— | $13.43M+509% | $5.2M+680% | ||
| $3.29M+204% | —— | —— | $9.82M+51,800% | $1.08M+240% | ||
| -$2.28M+14.9% | —— | —— | -$357K— | -$2.68M+29.7% | ||
| $25.68M-27.6% | $43.69M+31.9% | $60.83M+12.8% | $12.01M-77.4% | $35.46M-27.8% | ||
| $2.72M-68.1% | $218K-89.7% | $3.87M-5.4% | $2.7M+69.6% | $8.55M+201% | ||
| $335K-98.0% | —— | —— | —— | $16.7M— | ||
| $0-100% | $27.59M-39.0% | $38.77M-61.7% | $5.06M-89.8% | $69.63M+24.2% | ||
| $22.5M-67.5% | $47.14M+0.4% | $86.25M+62.2% | $71.17M+97.1% | $69.25M+59.7% | ||
| $19.44M+176% | $19.33M+5,354% | $43.61M+184% | $62.16M+509% | -$25.63M-65.0% | ||
| $50.05M— | $48.25M+672% | $50.04M+701% | $50.04M+701% | $0-100% | ||
| $5M— | $5M— | —— | —— | $0— | ||
| $2K— | $490K— | —— | —— | $0— | ||
| $4.36M+2,306% | $143K+85.7% | $8K-75.0% | $5.29M+1,298% | $181K+4,425% | ||
| -$59.4M-1,884% | -$51.65M— | -$257.48M— | -$57.51M-330% | -$2.99M-6.3% | ||
| $38K— | -$414K— | $133K— | $204K— | $0— | ||
| -$14.24M-308% | $0-100% | -$152.9M— | $16.87M-73.2% | $6.84M-77.8% | ||
| $1.6M-41.3% | $4.85M-7.3% | $2.7M-15.6% | $4.97M+64.7% | $2.72M-31.6% | ||
| $50K-82.5% | —— | $711K-85.5% | $7.95M+61.8% | $286K+217% | ||
| $570K-70.2% | —— | —— | —— | $1.91M+3.0% | ||
| $577K-33.4% | —— | —— | —— | $867K+7.6% | ||
| -$2.28M+14.9% | —— | —— | -$357K— | -$2.68M+29.7% | ||
| —— | $0+100% | $0+100% | $0+100% | $0+100% | ||
| —— | $1.71M-52.5% | $1.71M-52.5% | $1.71M-52.5% | $1.71M-52.5% | ||
| $4.54M-12.8% | —— | —— | $13.43M+509% | $5.2M+680% | ||
| $0+100% | —— | —— | —— | -$5.89M-8,164% | ||
| $0-100% | $27.59M-39.0% | $38.77M-61.7% | $5.06M-89.8% | $69.63M+24.2% | ||
| $22.5M-67.5% | $47.14M+0.4% | $86.25M+62.2% | $71.17M+97.1% | $69.25M+59.7% | ||
| $0-100% | —— | —— | —— | $2.81M— | ||
| $1.36M+77.6% | $352K-93.2% | —— | $664K— | $767K+26.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $448K— | $448K— | $448K— | $448K— | ||
| $50K-82.5% | —— | $711K-85.5% | $7.95M+61.8% | $286K+217% | ||
| $22.96M-14.7% | $43.47M+40.2% | $56.96M+14.3% | $9.32M-82.0% | $26.91M-41.8% | ||
| $22.96M-14.7% | $43.47M+40.2% | $56.96M+14.3% | $9.32M-82.0% | $26.91M-41.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacira BioSciences, Inc. generate?
- Pacira BioSciences, Inc. (PCRX) generated $142.2M in operating cash flow over the trailing twelve months.
- What is Pacira BioSciences, Inc.'s free cash flow?
- After $9.5M of capital expenditures, Pacira BioSciences, Inc.'s free cash flow was $132.7M over the trailing twelve months, down 16.8% year over year.
- Where does Pacira BioSciences, Inc.'s cash flow data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
